Sandoz has completed Phase III trials of its recombinant interleukin-3, a therapy which may be of use in preventing or treating the hematological side effects of cytotoxic cancer chemotherapy.
Early trials with the agent have indicated that it is very effective in reducing the frequency of life-threatening hematological side effects and may enable more patients to receive optimal chemotherapeutic regimens, according to Athos Gianella Borradori, head of oncology and hematology at Sandoz-Pharma in Basel, Switzerland.
Phase I and II trials of IL-3 in over 2,000 patients have shown that the drug significantly reduces the duration of patients' episodes of thrombocytopenia and neutropenia after chemotherapy for ovarian cancer, relapsed lymphoma, breast cancer and other malignancies. Dr Borradori said that as a result patients were at less risk of life-threatening bleeding episodes and infections, and could undergo further cycles of chemotherapy without delays or dose reductions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze